Publications
394
Citations
16,191
Est. group size
—
Recurring co-author estimate
Active years
29
Publishing since 1998
Kieren J. Mather conducts clinical research in diabetes and obesity medicine, focusing on how new drug therapies affect blood sugar control, insulin sensitivity, pancreatic beta-cell function, and body weight. Much of the recent work involves clinical trials of hormone-based medications (such as GLP-1, GIP, amylin, and glucagon receptor agonists) for type 2 diabetes, obesity, and related liver conditions. The research also examines cardiovascular risk factors and metabolic complications associated with these conditions.
Publication activity has remained steady, averaging roughly 16 to 33 papers per year across the last decade with no clear long-term decline.
Generated by claude-opus-4-8 from public bibliographic data · Jul 11, 2026
- Eloralintide, a selective, long‐acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept
Diabetes Obesity and Metabolism · 2026
- Prevalence of complications and comorbidities associated with obesity: a health insurance claims analysis
BMC Public Health · 2025
- Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
The Lancet · 2025
- Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes
Cardiovascular Diabetology · 2025
- Greater improvement in insulin sensitivity per unit weight loss associated with tirzepatide versus semaglutide: An exploratory analysis
Diabetes Obesity and Metabolism · 2025
- Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept
Molecular Metabolism · 2025
- Orforglipron, an oral non‐peptide glucagon‐like peptide‐1 receptor agonist, improves markers of β‐cell function and insulin sensitivity in type 2 diabetes
Diabetes Obesity and Metabolism · 2025
- Relationship Between Metabolic and Histological Responses in People With Metabolic Dysfunction– Associated Steatohepatitis With and Without Type 2 Diabetes: Participant-Level Exploratory Analysis of the SYNERGY-NASH Trial With Tirzepatide
Diabetes Care · 2025
- Mazdutide reduces body weight in adults with overweight or obesity: A high‐dose Phase 1 trial
Diabetes Obesity and Metabolism · 2025
- Long-acting GIPR agonist LY3537021 reduces body weight and fasting blood glucose in patients with T2D: Preclinical development and phase 1 randomized ascending dose studies
Molecular Metabolism · 2025
- 882-P: Eloralintide, a Selective, Long-Acting Amylin Receptor Agonist for Obesity—Phase 1 Proof of Concept
Diabetes · 2025
- A Long-acting Glucose-dependent Insulinotropic Polypeptide Receptor Agonist Improved Insulin Sensitivity and Beta-Cell Function in Participants with Type 2 Diabetes
Diabetologie und Stoffwechsel · 2025
- Orforglipron Improved Markers of Beta-Cell Function and Insulin Sensitivity in Type 2 Diabetes
Diabetologie und Stoffwechsel · 2025
- Retatrutide, an Agonist of GIP, GLP-1, and Glucagon Receptors, Improved Markers of Pancreatic Beta Cell Function and Insulin Sensitivity
Diabetologie und Stoffwechsel · 2025
- Author response for "Mazdutide reduces body weight in adults with overweight or obesity: A high-dose Phase 1 trial"
2025
- Diabetes×45
- Diabetes Care×34
- PMC×12
- Diabetes Obesity and Metabolism×9
- Diabetologie und Stoffwechsel×9
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 11, 2026.
Claim or correct this profile